
Top 5 Most-Read Articles From Evidence-Based Oncology™ for 2021
Articles on advances in immuno-oncology and non-small cell lung cancer were popular with readers in the past year.
The rise of immunotherapy and precision medicine in both non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) is reflected in this year’s list of most-read articles in Evidence-Based Oncology™, the multistakeholder publication of The American Journal of Managed Care®. Disease states that have historically been the top causes of cancer death have seen progress in recent years, but 2021 brought some controversy.
5. After PD-1 Inhibitor Indications Are Withdrawn in SCLC, What Now?
One of the biggest regulatory stories of the year in oncology was the tale of the “dangling approval.” FDA’s reliance on accelerated approvals to bring potential life-saving therapies to patients based on early evidence meant that those approvals might be withdrawn if phase 3 trials failed to confirm the results. This was the year that came to pass. FDA held a series of hearings in late April that to weigh whether the fate of certain indications in SCLC. But as Martin J. Edelman, MD, of Fox Chase Cancer Center in Philadelphia, Pennsylvania, explained in
4. Possible Treatment Identified for Aggressive NSCLC Subset
This article from our
3. Real-World Evidence Is Key to Accelerating Oncology Approvals
In our
2. FDA Grants Tiragolumab Breakthrough Therapy Designation for PD-L1 High NSCLC
Another update from
1. FDA Approves Tagrisso for Adjuvant Treatment of Early Stage EGFR Mutated NSCLC
This approval for osimertinib (Tagrisso) reported
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.